PLX

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024
Infection, Therapy, Bangladesh Technical Education Board, Parity, AFRRI, USUHS, Cocaine, Medicine, NIAID, NIH, Bar-Ilan University, PLUR, World War II, FDA, PLX, Partnership, 3D, Food, Ageing, GMP, Hope, BIRAD, Plural, Meat, Risk, Outline of health sciences, CDMO, Climate, Climate change, Health, Water, Food and Drug Administration, Coffee, Knowledge, Agriculture, Food security, Negotiation, Good manufacturing practice, Pharmaceutical industry

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

Luxium Solutions to Acquire PLX

Retrieved on: 
Monday, March 4, 2024
Other Defense, Contracts, Finance, Chemicals, Plastics, Aerospace, Professional Services, Manufacturing, Government Technology, Defense, Acquisition, System, Vaccine, PLX, Growth, Environmental monitoring, KeyBank, Latham & Watkins, Knowledge, Metrology, Partnership

Luxium Solutions, LLC (“Luxium” or the “Company”), a worldwide technology leader and provider of high-performance crystals used in photonics and radiation detection applications, has entered into an agreement to acquire PLX Inc. and PLX UK, Ltd, (collectively, “PLX”) from an investor group led by Tinicum.

Key Points: 
  • Luxium Solutions, LLC (“Luxium” or the “Company”), a worldwide technology leader and provider of high-performance crystals used in photonics and radiation detection applications, has entered into an agreement to acquire PLX Inc. and PLX UK, Ltd, (collectively, “PLX”) from an investor group led by Tinicum.
  • “Both Luxium and PLX bring complementary technical expertise in applied material sciences to enable the applications of our customers.
  • Luxium and PLX share a strong alignment in their go-to-market strategies emphasizing collaboration with customers to develop customized solutions.
  • Furthermore, it’s clear that both companies share common values grounded in scientific excellence, quality, and customer satisfaction,” said Itai Vishnia, CEO of PLX, who will continue to lead the PLX group within the Luxium portfolio.

Historic milestone for Pluxee, now listed on Euronext Paris following its spin-off from Sodexo

Retrieved on: 
Thursday, February 1, 2024
Partnership, Growth, Employee engagement, Employee benefits, Capital market, SME, Marketing, Drive, Acquire, Engagement, PLX, EUR, Management

On February 1, 2024, Pluxee’s shares were distributed to Sodexo shareholders on a one-for-one basis.

Key Points: 
  • On February 1, 2024, Pluxee’s shares were distributed to Sodexo shareholders on a one-for-one basis.
  • The technical reference price of EUR 26 per Pluxee share was announced on January 31, 2024, by Euronext.
  • “By successfully completing Pluxee’s spin-off and listing on Euronext Paris, we take a further step towards the accomplishment of our longstanding vision.
  • This is the beginning of a new era and I would like to thank the entire team for their hard work.

Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024

Retrieved on: 
Friday, February 2, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Transverse mode, Drug discovery, RNA interference, AAV, HCS, Drug development, PLX, Medicine, Genomics, CDX, CRISPR, G3, NGS, SLAS, GMP, Automation, Flow cytometry, Omics, Engineering, TB

As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health.

Key Points: 
  • As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health.
  • Its offerings are designed to provide differentiated capabilities, providing customers with tools needed for success in precision medicine and beyond.
  • Dr. Alan Fletcher, Revvity’s senior vice president, life sciences, stated, "We're here in our backyard showing how we're seamlessly bringing it all together, powering innovation from research to reality.
  • Revvity will be exhibiting a selection of its extensive range of life sciences and diagnostics products and services.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023
Bar-Ilan University, Cocaine, Depression, FDA, Crime, PLUR, Pharmaceutics, Plural, PLX, Brain, Drug, Research, Rat, BIRAD, PTSD, Anxiety, U.N, Neurogenesis, Cell, Neuron, PAD, Pharmaceutical industry

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.

Levicept Appoints Eliot Forster as CEO

Retrieved on: 
Thursday, November 30, 2023
AMEX, Pain, Chronic pain, Tessellation, Osteoarthritis, PLX, AIM, GSK, CSO, Patient, Medicine, Pharmaceutical industry

SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO.

Key Points: 
  • SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO.
  • Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance.
  • Eliot was most recently CEO of F-star (NASDAQ:FSTX), a clinical-stage, NASDAQ-listed biotech that was acquired by inovX Pharma limited in March 2023.
  • Eliot Forster, CEO of Levicept, said, “The safe and effective management of chronic pain remains a critical need in medicine.

Bitget Marks Exclusive Listing of PLEXUS (PLX) Token: Propelling Cross-Chain DEX Aggregator to the Forefront

Retrieved on: 
Thursday, December 14, 2023
Theta, Cross, CCRP, PLX, DEX, Decentralized finance, Ecosystem, Cryptocurrency, Bitget

Bitget Marks Exclusive Listing of PLEXUS (PLX) Token: Propelling Cross-Chain DEX Aggregator to the Forefront

Key Points: 
  • Bitget Marks Exclusive Listing of PLEXUS (PLX) Token: Propelling Cross-Chain DEX Aggregator to the Forefront
    The issuer is solely responsible for the content of this announcement.
  • Bitget, a leading cryptocurrency exchange and Web3 company, proudly announces its exclusive listing of PLEXUS (PLX) token, positioning the platform as the premier gateway for the revolutionary Cross-chain DEX aggregator on its debut day.
  • PLEXUS stands out as a Cross-chain DEX aggregator, promising the fastest, most cost-efficient, and secure multi-step swaps across diverse blockchain networks and bridges—all within a single transaction.
  • By facilitating the debut of this revolutionary Cross-chain DEX aggregator, Bitget continues its commitment to fostering user-centric innovation and propelling the industry toward a more accessible and integrated future.

Delisting of Securities of Pingtan Marine Enterprise Ltd.; SRAX, Inc.; SVB Financial Group; Signature Bank; Codiak BioSciences, Inc.; PLx Pharma Inc.; Virgin Orbit Holdings, Inc.; Kalera Public Limited Company; Pear Therapeutics, Inc.; and Intelligent Med

Retrieved on: 
Friday, April 28, 2023
Federal Deposit Insurance Corporation, PLX, Signature Bank, FDIC, Bangladesh Securities and Exchange Commission, Delisting, SVB, Silicon, Therapy, News, Cryptocurrency

Nasdaq also announced today that it will delist the common stock and preferred stock of SVB Financial Group.

Key Points: 
  • Nasdaq also announced today that it will delist the common stock and preferred stock of SVB Financial Group.
  • SVB Financial Group securities were suspended on March 28, 2023, and have not traded on Nasdaq since that time.
  • Signature Bank securities were suspended on March 28, 2023, and have not traded on Nasdaq since that time.
  • Kalera Public Limited Company securities were suspended on April 17, 2023, and have not traded on Nasdaq since that time.

PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Pharmacodynamics, Private Securities Litigation Reform Act, Pharmacist, Sales, Intellectual property, Thrombosis, Marketing, PIN, Investment, OBI Pharma, Inc., Event, Patent, Aspirin, Communication, Income, Risk, Cardiology, Thrombolysis, Stomach, R, API, Mission statement, SEC, Failure, Net, NASDAQ, SM&A, SM, Company, Program, Journal, Research, Absorption, GAAP, Awareness, Patient, Pain, PLX, Corporate communication, Industry, FDA, HCPS, Trial of the century, Bank, Pharmaceutical industry, Medicine, Generic drug, Fine chemical, Video game, Facebook

SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), announced today certain financial and operational results for the three months ended September 30, 2022, and provided other business updates.

Key Points: 
  • Research and development (R&D) expenses declined approximately 60% to $0.6 million in the third quarter of 2022, compared to approximately $1.6 million in the third quarter of 2021.
  • The Companys 2022 third quarter conference call with analysts and investors will be held today at 8:30am ET.
  • To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com and follow us on LinkedIn and Twitter .
  • These forward-looking statements represent PLxs estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.

PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

Retrieved on: 
Wednesday, October 26, 2022
Company, Patent, NASDAQ, Risk, Webcast, Aspirin, Event, Corporate communication, PLX, Stomach, OBI Pharma, Inc., GLOBE, PIN, API, FDA, Absorption, Pain, Pharmaceutical industry, Generic drug

The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as VAZALORE), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022.

Key Points: 
  • The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as VAZALORE), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022.
  • Following the release, Company executives will host a conference call at 8:30 a.m.
  • ET with investors and analysts to discuss financial results and business progress.
  • To participate in the conference call, please click here to obtain your dial in number and PIN.